EmGenisys, an animal health startup specializing in artificial intelligence for livestock reproduction, has secured $1.5 million in seed funding to advance its embryo evaluation technology. The oversubscribed round was led by Grit Road Partners, with additional investment from agtech venture capital firms Tall Grass Ventures and Ag Venture Alliance.
The funding will support the continued development and global scaling of EmGenisys’ core technology, EmVision—a machine learning-powered platform that provides real-time embryo health analysis. Using 30-second videos captured by a smartphone mounted to a microscope, the web-based system assesses embryo viability frame by frame and delivers immediate health scores to aid in embryo selection.
By enabling embryologists, veterinarians, and cattle producers to make data-informed decisions, EmVision aims to improve pregnancy rates and optimize genetic investments across IVF and embryo transfer programs in the beef and dairy sectors.
Founded in 2020 by Dr. Cara Wells and Dr. Russell Killingsworth, EmGenisys has rapidly gained traction in the industry. The company holds 15 U.S. patents and has earned multiple awards, including the BioTools Innovator Award at Boston Biotech Week and the Animal Health Corridor Innovation Award in Kansas City.
With the new capital, EmGenisys plans to expand into additional livestock species and introduce new product offerings focused on improving reproductive success and genetic progress.
Investors say the company represents a new wave of innovation in livestock technology, combining AI with practical on-farm applications to solve real challenges in reproductive efficiency.
